Celebrate milestones, and dont be discouraged by occasional plateaus
These medications are quite expensive if theyre not covered by insurance, and a lot of people cant afford that. Foundayo and Zepbound now covered for millions of Americans
Experts also point out that the ingredients in the viral drops dont support the brand claims
Current and resolved drug shortages and discontinuations reported to the FDA, Food and Drug Administration (2024) Regulatory framework for compounded preparations, National Academies Press (2020) Clinical and legal considerations in pharmaceutical compounding, The Journal of Clinical and Aesthetic Dermatology (2023) FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Medications containing semaglutide marketed for Type 2 diabetes or weight loss, Food and Drug Administration (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders
